DRI Healthcare Trust (DHT-UN) Q2 2025 earnings summary

Executive summary

• Completed internalization of investment management on July 1, 2025, aligning interests, improving governance, and expected to generate $200 million in savings over 10 years, with a $48 million termination payment and $1 million asset acquisition.

• Portfolio assets performed as anticipated, with growth from Orserdu, Xolair, and new FDA approval for Ectorly/Ekterly, and a robust pipeline of over $3 billion in opportunities.

• CFO Amit Kapur to depart at the end of September after stabilizing the company and leading the internalization.

• Completed $22 million payment to increase Ectorly/Ekterly royalty entitlement and milestone potential.

• Portfolio of 28 royalty streams on 21 products generated $40.2 million in Q2 2025 cash receipts.

Financial highlights

• Q2 2025 Total Cash Receipts: $40.2 million, down 7% sequentially and year-over-year.

• Total Income: $44.1 million, up 6% year-over-year.

• Adjusted EBITDA: $30.4 million, down 8% year-over-year, margin 76%-80% (87% excluding non-recurring expenses).

• Adjusted Cash Earnings per Unit: $0.51 for Q2 2025; trailing 12 months $2.15.

• Cash and equivalents at June 30, 2025: $82.5 million; credit facility availability: $273.1 million.

Outlook and guidance

• Expect adjusted EBITDA margins to return to historical levels post-internalization and aim to distribute 20%-30% of free cash flow to unitholders.

• Anticipate stronger performance from Ectorly/Ekterly, continued outperformance from Orserdu and Xolair, and stabilization of Omidria and Bonjour.

• Focus on sustainable growth, strong governance, and execution on a robust investment pipeline.

• Pipeline of royalty opportunities remains robust, with over $3 billion under review.

• Forward-looking statements highlight risks from competition, generic entry, and global economic conditions.